Here, we systematically examined the effects of ipatasertib on patient-derived glioblastoma cells and additionally compared the results with four other SMIs addressing targets in the PI3K/AKT/mTOR and MAPK signaling pathway with different mechanisms of action. This evidence concerns the gene AKT1 and glioblastoma.